April 4, 2011
Bookmark and Share  
 
  HCV
»
»
»
»

 

Greetings:

This week’s postings include:

Top News from EASL 2011: Here are a few highlights:

  • Quadruple therapy shows 100 percent SVR for HCV patients previously unresponsive to treatment.

  • FDA Fast Track designations granted for both the protease inhibitor BI 201335 plus standard-of-care and the interferon-free combination of BI 201335 with polymerase inhibitor, BI 207127.

  • PegIFN-lambda shows superior virological response and improved safety than PegIFN-alpha-2a.

  • First Vaccine For Viral Hepatitis C Could Become A Reality.

April 2011 HCV Advocate newsletter that includes:

  • Why We Should Test—Editorial: Testing everyone for HCV regardless of medical coverage is a very contentious issue, Now that we will have new response-guided treatment regimens and rapid testing, it may be time to take another look.

  • HCV Snapshots this month is a pot pourri of interesting items from Silibinin monotherapy to IL28B Genomic-based Treatment Paradigms.

  • Liver Transplantation: HCV Recurrence and Treatment, by Liz Highleyman, is a must read.

  • HEALTHWISE: Humor, Health, and Hepatitis C is yet another delightful essay, by Lucinda K. Porter, RN., on living with hepatitis C.

April HBV Journal Review that includes: 

  • Rate of HBV drops in the U.S.

  • Screening All Chemotherapy Patients for Hepatitis B.

  • Connections between Hepatitis B and Diabetes.

  • Biopsy and Treatment Recommended in HBeAg-negative Patients.

  • Immunization at Birth Reduces Infection, but Parents May Still Transmit Infection.

  • HIV-HBV Coinfected Face Higher Death Rates than HIV-HCV Coinfected.

                      …..and more

 

New Hepatitis & Tattos Blog: Be sure to check out and participate in our new blog.

 

Don’t forget to check out our HCV & HBV Advocate Hepatitis Blog for more about the most recent news stories.

 

 

Sincerely,
Alan

 

Alan Franciscus
Executive Director, Hepatitis C Support Project
Editor-in-Chief, HCV Advocate www.hcvadvocate.org
Editor-in-Chief, HBV Advocate www.hbvadvocate.org

.

**Questions and Comments: Questions and/or comments can be directed to alanfranciscus@hcvadvocate.org

**To receive the eblast in your email inbox simply send an e-mail to: listserv@list.hcvadvocate.org with nothing in the subject line and the following in the message body: subscribe emailalert. Make sure your email address is all lower case.

.

  HBV
»
»
»
»